Henkels KM, et al. (2011) Cell Invasion of Highly Metastatic MTLn3 Cancer Cells Is Dependent on Phospholipase D2 (PLD2) and Janus Kinase 3 (JAK3). J Mol Biol 408, 850-62 21414324

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y415-p - PLD2 (human) ▲

Modsite: ALGINSGysKRALML SwissProt Entrez-Gene Orthologous residues PLD2 (human): Y415‑p, PLD2 (mouse): Y415‑p, PLD2 (rat): Y415‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  breast cancer, lung cancer, non-small cell lung cancer Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), MDA-MB-231 (breast cell), MTLn3 (breast cell), NCI-H1299 (pulmonary) Cellular systems studied:  cell lines Species studied:  human, rat Enzymes shown to modify site in vitro:  Type Enzyme KINASE JAK3 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE JAK3 (human) siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes siRNA decrease JAK3 siRNA Downstream Regulation Effect of modification (function):  enzymatic activity, induced Effect of modification (process):  carcinogenesis, induced, cell motility, induced